Nipent Related Published Studies
Well-designed clinical trials related to Nipent (Pentostatin)
Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. [2011.01.20]
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. [2009.07.16]
Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. [2000.11.01]
Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. [1995.04]
Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs. [1995.03]
Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group. [1994]
Well-designed clinical trials possibly related to Nipent (Pentostatin)
Graft-versus-host disease treatment: predictors of survival. [2010.12]
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. [2006.08]
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. [2006.08]
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. [1994]
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. [1994]
Lack of significant activity of 2'-deoxycoformycin alone or in combination with adenine arabinoside in relapsed childhood acute lymphoblastic leukemia. A randomized phase II trial from the Childrens Cancer Study Group. [1992.12]
Treatment of hairy-cell leukemia. [1990.12]
Hairy cell leukemia. Current management. [1990.04]
Other research related to Nipent (Pentostatin)
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. [2011.09.16]
Pentostatin for treatment of refractory autoimmune lymphoproliferative syndrome. [2011.08]
Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas. [2011.06]
Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. [2011.06]
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. [2011.06]
Mechanism of action of pentostatin and cladribine in hairy cell leukemia. [2011.06]
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. [2011.05]
Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis. [2011.04]
Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. [2010.12.22]
Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. [2010.05.01]
Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. [2009.11.12]
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. [2009.11.10]
Pentostatin treatment combinations in chronic lymphocytic leukemia. [2009.06]
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. [2009.06]
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. [2009.01.15]
Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. [2009]
Pentostatin in chronic lymphocytic leukemia. [2008.09]
Therapeutic benefit of pentostatin in severe IL-10-/- colitis. [2008.07]
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. [2007.11.15]
Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. [2007.09.20]
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. [2007.06.01]
Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. [2007.04]
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. [2007.01.15]
Possible pentostatin-induced symptomatic hyponatremia. [2007.01]
Pentostatin: impact on outcome in hairy cell leukemia. [2006.10]
Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. [2006.09.28]
A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma. [2006.05]
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. [2006.04.01]
Pentostatin and purine analogs for indolent lymphoid malignancies. [2006.04]
Pentostatin for the treatment of indolent lymphoproliferative disorders. [2006.04]
Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. [2006.01]
Prolonged allogeneic marrow engraftment following nonmyeloablative conditioning using 100 cGy total body irradiation and pentostatin before and pharmacological immunosuppression after transplantation. [2005.11.27]
[Pentostatin treatment for a patient with chronic type adult T-cell leukemia undergoing hemodialysis] [2005.11]
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. [2005.09]
Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. [2005.08]
Pentostatin in steroid-refractory acute graft-versus-host disease. [2005.04.20]
An open-label pilot study of pentostatin, mitoxantrone, and rituximab in patients with previously untreated, Stage III or IV, low-grade non-Hodgkin lymphoma. [2005.03.01]
Pentostatin (2'-deoxycoformycin) for the treatment of hepatosplenic gammadelta T-cell lymphomas. [2005.03]
Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease. [2004.12]
Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. [2004.02]
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. [2004.01.15]
Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. [2004.01]
Results of a phase II multicenter trial of pentostatin and rituximab in patients with low grade B-cell non-Hodgkin's lymphoma: an effective and minimally toxic regimen. [2003.12]
Granulomatous slack skin disease--disease features and response to pentostatin. [2003.10]
Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation. [2003.09.15]
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. [2003.09]
Pentostatin for the treatment of chronic graft-versus-host disease in children. [2003.07]
Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab. [2003.05]
Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. [2003.04.01]
Pentostatin in the treatment of hairy-cell leukemia. [2003.03]
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. [2003.01]
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. [2002.08]
Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. [2002.07]
Therapy of T cell lymphomas with pentostatin. [2001.09]
[Successful treatment of hairy cell leukemia with pentostatin] [2001.07]
Infectious complications of pentostatin therapy. [2000.06]
Pentostatin treatment of cutaneous T-cell lymphoma. [2000.06]
Pentostatin and rituximab in the treatment of patients with B-cell malignancies. [2000.06]
An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease. [2000.04]
Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders. [2000.04]
Pentostatin (Nipent) in T-cell lymphomas. [2000.04]
Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. [2000.04]
Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer. [2000.04]
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. [2000.04]
A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia. [2000.04]
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders. [2000.04]
Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. [2000.04]
Phase II trials of pentostatin (Nipent) in hairy cell leukemia. [2000.04]
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. [2000.04]
Future directions for pentostatin (Nipent) usage in dermatology. [2000.04]
Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group. [1999.12]
Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. [1999.10]
Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. [1999.08]
Long term outcome of patients with hairy cell leukemia treated with pentostatin. [1999.01.01]
[Effective pentostatin-based treatment of adult T cell leukemia in a patient with severe arthritis] [1998.07]
Persistent bone marrow failure with dysplastic features following pentostatin therapy for hairy cell leukaemia. [1998.06]
Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia. [1998.01]
Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. [1998]
Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. [1997.06]
Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. [1996.03]
Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases. [1996]
Immunosuppressive effect of 2'-deoxycoformycin (Pentostatin) for rat islet allotransplantation. [1995.05]
Mutagenesis of human adenosine deaminase to active forms that partially resist inhibition by pentostatin. [1995.04.17]
The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. [1994.12]
Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. [1994.12]
Salvage chemotherapy with pentostatin in prolymphocytic leukemia. [1994.11]
Pentostatin-augmented interstitial adenosine prevents postcardioplegia injury in damaged hearts. [1994.09]
|